Cogle Christopher R, Imanirad Iman, Wiggins Laura E, Hsu Jack, Brown Randy, Scornik Juan C, Wingard John R
Division of Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA.
Clin Adv Hematol Oncol. 2010 Jan;8(1):40-6.
Disease remission in patients with myelodysplastic syndromes can be achieved with azanucleosides, which act as pyrimidine analogs and hypomethylating agents. However, despite treatment with azanucleoside induction, patients with myelodysplastic syndromes nearly always relapse. Allogeneic hematopoietic cell transplantation (HCT) can be curative, but it is risky. Given that azanucleosides affect human leukocyte antigen expression and lymphocyte reactivity, we conducted a retrospective study to define the impact of pre-HCT azanucleoside therapy on post-HCT donor chimerism. Patients receiving azanucleoside induction therapy achieved rapid and high levels of donor chimerism post-transplant. Lineage analysis also found rapid donor chimerism of lymphocyte and granulocyte subsets. These data indicate the feasibility of pretransplant azanucleoside therapy in patients who subsequently receive an HCT.
骨髓增生异常综合征患者可通过氮杂核苷实现疾病缓解，氮杂核苷作为嘧啶类似物和低甲基化剂发挥作用。然而，尽管接受了氮杂核苷诱导治疗，骨髓增生异常综合征患者几乎总会复发。异基因造血细胞移植（HCT）可能治愈疾病，但存在风险。鉴于氮杂核苷会影响人类白细胞抗原表达和淋巴细胞反应性，我们进行了一项回顾性研究，以确定移植前氮杂核苷治疗对移植后供体嵌合现象的影响。接受氮杂核苷诱导治疗的患者在移植后实现了快速且高水平的供体嵌合。谱系分析还发现淋巴细胞和粒细胞亚群的供体嵌合现象迅速。这些数据表明，在随后接受HCT的患者中，移植前使用氮杂核苷治疗是可行的。
